Estrogen
Active ingredient: Estrogens, Conjugated
In short: Limitations of Use When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered. Limitations of Use When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only
What is Estrogen used for?
Limitations of Use
When prescribing solely for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy due to menopause, topical vaginal products should be considered.
Limitations of Use
When prescribing solely for the prevention of postmenopausal osteoporosis, therapy should only be considered for women at significant risk of osteoporosis and non-estrogen medication should be carefully considered.
âš Boxed warning (FDA's strongest warning)
Estrogen-Alone Therapy
Endometrial Cancer
There is an increased risk of endometrial cancer in a woman with a uterus who uses unopposed estrogens. Adding a progestin to estrogen therapy has been shown to reduce the risk of endometrial hyperplasia, which may be a precursor to endometrial cancer. Adequate diagnostic measures, including directed or random endometrial sampling when indicated, should be undertaken to rule out malignancy in postmenopausal women with undiagnosed persistent or recurring abnormal genital bleeding .
Cardiovascular Disorders and Probable Dementia
Estrogen-alone therapy should not be used for the prevention of cardiovascular disease or dementia .
The Women's Health Initiative (WHI) estrogen-alone substudy reported increased risks of stroke and deep vein thrombosis (DVT) in postmenopausal women (50 to 79 years of age) during 7.1 years of treatment with daily oral conjugated estrogens (CE) (0.625 mg)-alone, relative to placebo.
The WHI Memory Study (WHIMS) estrogen-alone ancillary study of WHI reported an increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 5.2 years of treatment with daily CE (0.625 mg)-alone, relative to placebo. It is unknown whether this finding applies to younger postmenopausal women [see Warnings and Precautions (5.3), Use in Specific Populations (8.5), and Clinical Studies (14.6)].
In the absence of comparable data, these risks should be assumed to be similar for other doses of CE and other dosage forms of estrogens. …
Estrogen dosage
Generally, when estrogen therapy is prescribed for a postmenopausal woman with a uterus, a progestin should be considered to reduce the risk of endometrial cancer .
A woman without a uterus does not need progestin. In some cases, however, hysterectomized women with a history of endometriosis may need a progestin .
Use of estrogen-alone, or in combination with a progestin, should be with the lowest effective dose and for the shortest duration consistent with treatment goals and risks for the individual woman. Postmenopausal women should be re-evaluated periodically as clinically appropriate to determine if treatment is still necessary.
Conjugated estrogens tablets may be taken without regard to meals.
Patients should be treated with the lowest effective dose. Generally, women should be started at 0.3 mg conjugated estrogens tablets daily. Subsequent dosage adjustment may be made based upon the individual patient response. This dose should be periodically reassessed by the healthcare provider.
Conjugated estrogens tablets therapy may be given continuously, with no interruption in therapy, or in cyclical regimens (regimens such as 25 days on drug followed by 5 days off drug), as is medically appropriate on an individual basis.
Patients should be treated with the lowest effective dose. Generally, women should be started at 0.3 mg conjugated estrogens tablets daily. Subsequent dosage adjustment may be made based upon the individual patient response. This dose should be periodically reassessed by the healthcare provider.
Conjugated estrogens tablets therapy may be given continuously, with no interruption in therapy, or in cyclical regimens (regimens such as 25 days on drug followed by 5 days off drug), as is medically appropriate on an individual basis.
Conjugated estrogens tablets therapy should be initiated and maintained with the lowest effective dose to achieve clinical goals. Female hypogonadism: 0.3 mg or 0.625 mg daily, administered cyclically (e.g., three weeks on and one week off). Doses are adjusted depending on the severity of symptoms and responsiveness of the endometrium .
Female castration or primary ovarian failure: 1.25 mg daily, cyclically. Adjust dosage, upward or downward, according to severity of symptoms and response of the patient. For maintenance, adjust dosage to lowest level that will provide effective control.
Suggested dosage is 10 mg three times daily, for a period of at least three months.
2x0.625 mg to 4x0.625 mg three times daily. The effectiveness of therapy can be judged by phosphatase determinations as well as by symptomatic improvement of the patient. …
How to take Estrogen — instructions & advice from the label
Advise the patients to read the FDA-approved patient labeling (Patient Information).
Inform postmenopausal women of the importance of reporting vaginal bleeding to their healthcare provider as soon as possible .
Inform postmenopausal women of possible serious adverse reactions of estrogen therapy including Cardiovascular Disorders, Malignant Neoplasms, and Probable Dementia .
Inform postmenopausal women of possible less serious but common adverse reactions of estrogen therapy such as headache, breast pain and tenderness, nausea and vomiting.
Iss: 05/2026
I0152
Rev C
Manufactured for:
Ingenus Pharmaceuticals, LLCOrlando, FL 32811-7193Product of China
Warnings & precautions
Do not take this medicine if: Conjugated estrogens tablets therapy is contraindicated in individuals with any of the following conditions:
• Undiagnosed abnormal genital bleeding
• Breast cancer or a history of breast cancer except in appropriately selected patients being treated for metastatic disease
• Estrogen-dependent neoplasia
• Active DVT, PE, or a history of these conditions
• Active arterial thromboembolic disease (for example stroke and MI), or a history of these conditions
• Known anaphylactic reaction or angioedema with conjugated estrogens tablets
• Hepatic impairment or disease
• Protein C, protein S or antithrombin deficiency, or other known thrombophilic disorders.
An increased risk of stroke and DVT has been reported with estrogen-alone therapy. An increased risk of PE, DVT, stroke and MI has been reported with estrogen plus progestin therapy. Should any of these events occur or be suspected, estrogen with or without progestin therapy should be discontinued immediately.
Risk factors for arterial vascular disease (for example, hypertension, diabetes mellitus, tobacco use, hypercholesterolemia, and obesity) and/or venous thromboembolism (VTE) (for example, personal or family history of VTE, obesity, and systemic lupus erythematosus) should be managed appropriately.
Stroke
In the WHI estrogen-alone substudy, a statistically significant increased risk of stroke was reported in women 50 to 79 years of age receiving daily CE (0.625 mg)-alone compared to women in the same age group receiving placebo (45 versus 33 per 10,000 women-years). The increase in risk was demonstrated in Year 1 and persisted . Should a stroke occur or be suspected, estrogen-alone therapy should be discontinued immediately. …
Estrogen side effects
The following serious adverse reactions are discussed elsewhere in labeling:
•Cardiovascular Disorders
•Malignant Neoplasms
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.
During the first year of a 2-year clinical trial with 2,333 postmenopausal women with a uterus between 40 and 65 years of age (88% Caucasian), 1,012 women were treated with CE, and 332 were treated with placebo.
Table 1 summarizes treatment-related adverse reactions that occurred at a rate of ≥ 1% in any treatment group.
Table 1: Treatment-Related Adverse Reactions at a Frequency ≥1%
Conjugated estrogens tablets
0.625 mg
(n=348) | Conjugated estrogens tablets
0.45 mg (n=338) | Conjugated estrogens tablets
0.3 mg
(n=326) | Placebo
(n=332)
Body as a whole
Abdominal pain | 38 (11) | 28 (8) | 30 (9) | 21 (6)
Asthenia | 16 (5) | 8 (2) | 14 (4) | 3 (1)
Back pain | 18 (5) | 11 (3) | 13 (4) | 4 (1)
Chest pain | 2 (1) | 3 (1) | 4 (1) | 2 (1)
Generalized edema | 7 (2) | 6 (2) | 4 (1) | 8 (2)
Headache | 45 (13) | 47 (14) | 44 (13) | 46 (14)
Moniliasis | 5 (1) | 4 (1) | 4 (1) | 1 (0)
Pain | 17 (5) | 10 (3) | 12 (4) | 14 (4)
Pelvic pain | 10 (3) | 9 (3) | 8 (2) | 4 (1)
Cardiovascular system
Hypertension | 4 (1) | 4 (1) | 7 (2) | 5 (2)
Migraine | 7 (2) | 1 (0) | 0 | 3 (1)
Palpitation | 3 (1) | 3 (1) …
Drug interactions
Data from a single-dose drug-drug interaction study involving CE and MPA indicate that the pharmacokinetic disposition of both drugs is not altered when the drugs are coadministered. No other clinical drug-drug interaction studies have been conducted with CE.
In vitro and in vivo studies have shown that estrogens are metabolized partially by cytochrome P450 3A4 (CYP3A4). Therefore, inducers or inhibitors of CYP3A4 may affect estrogen drug metabolism. Inducers of CYP3A4, such as St. John’s Wort (Hypericum perforatum) preparations, phenobarbital, carbamazepine, and rifampin, may reduce plasma concentrations of estrogens, possibly resulting in a decrease in therapeutic effects and/or changes in the uterine bleeding profile. Inhibitors of CYP3A4, such as erythromycin, clarithromycin, ketoconazole, itraconazole, ritonavir and grapefruit juice, may increase plasma concentrations of estrogens and may result in side effects.
About this medicine
Conjugated estrogens tablets, USP for oral administration contains a mixture of CE purified from pregnant mares' urine and consists of the sodium salts of water-soluble estrogen sulfates blended to represent the average composition of material derived from pregnant mares' urine. It is a mixture of sodium estrone sulfate and sodium equilin sulfate. It contains concomitant components as sodium sulfate conjugates, 17α-dihydroequilin, 17α-estradiol, and 17β-dihydroequilin. Tablets for oral administration are available in 0.3 mg, 0.45 mg, and 0.625 mg strengths of CE.
Conjugated estrogens tablets USP, 0.3 mg, 0.45 mg, and 0.625 mg tablets also contain the following inactive ingredients: hypromellose, lactose monohydrate, magnesium stearate, microcrystalline cellulose, polyethylene glycol, povidone, sodium acetate anhydrous, and titanium dioxide. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID b17eca23-f387-4243-a76a-bcf6b88aeef9. Read the full official label on DailyMed.
Related medicines
Levothyroxine Ergocalciferol Estradiol Ethinyl Estradiol and Norethindrone Alendronate Testosterone Thyroid Norethindrone